Abstract 409P
Background
Tertiary lymphoid structures (TLS) have been associated with tumor response to checkpoint inhibitors (ICIs) in soft tissue sarcoma as well as several epithelial cancers. However, its role in bone sarcoma has not been thoroughly investigated to date.
Methods
We retrospectively evaluated the presence of TLS by histology examination in 75 osteosarcoma specimens, including 29 primary lesions and 46 recurrent lesions. There were 48 males and 27 females, with a median age of 16(range 7∼57) yo. RNA-seq was performed to interrogate the immune cell infiltration, B-cell receptor (BCR) repertoire as well B cell activity-related pathways. The therapeutic response of ICIs in relation to TLS was also investigated in 31 patients with advanced osteosarcoma.
Results
We observed the presence of tumor-associated TLS in 13(17.3%), TLS outside the tumor in 16 (21.3%), absence of TLS in 32 (42.7%) samples and not evaluable in 14 (18.7%) samples. Surprisingly, the mPFS following ICI was 5.5 months in patients with tumor-associated TLS, yet tremendously shorter in patients with TLS outside tumor (2.0 months) or without TLS (3.0 months). Additionally, we found the majority of tumor-associated TLS were located peri-tumor (11) rather than intra-tumor (2), indicating a potential suppressive microenvironment of TLS formation. There was no association of age, gender, lymph node status, and metastasis burden with the presence of TLS. However, metastatic lesions and tumors pretreated with gemcitabine-docetaxel were more likely to be TLS-present. Interestingly, the presence TLS was significantly associated with T cell activation and NK cell activity in the tumor microenvironment. Higher clonality, but not diversity or richness, of BCR repertoire found in TLS-present tumors suggested the role of BCR clonal expansion in antitumor activity. Furthermore, we observed an upregulation of numerous targetable checkpoint molecules associated with TLS-present tumors, such as TIM3, VISTA, PD-L1, PD-1, LAG3, IDO, CTLA4, CD40, etc.
Conclusions
Our report suggested the presence of TLS as a potential biomarker and the induction of TLS as an appealing strategy to boost ICI immunotherapy in osteosarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ruijin Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06